Trabectedin is approved in Europe for the treatment of patients with advanced soft-tissue sarcoma (STS) after failure of anthracyclines and ifosfamide, or when they are not eligible to receive these agents. In this setting, the 6-month progression-free rate is about 35--40% ([@bib9]; [@bib24]; [@bib16]; [@bib7]; [@bib2]).The identification of predictive biomarkers of the clinical benefit of trabectedin in STS patients is thus a crucial issue to identify potential responders.

Even though the exact action mechanisms of trabectedin are not yet fully known, previous *in vitro* studies have demonstrated that the action depends on the status of both nucleotide excision repair and homologous recombination (HR) DNA repair pathways ([@bib6]; [@bib8]; [@bib22]; [@bib11]; [@bib21]). It was shown that cells deficient in HR were more sensitive to trabectedin than their nondeficient counterparts owing to the persistence of DNA lesions and increased formation of double-strand breaks (DSBs) ([@bib21]). *BRCA1*, a key regulator involved in DNA-end resection during HR ([@bib12]), was part of the gene expression signature, associated with sensitivity to trabectedin in human sarcoma cells explanted from patients not previously treated by chemotherapy ([@bib17]). Consistent with other publications ([@bib19]), we have reported that the expression of *ERCC1 and ERCC5* genes may be associated with clinical benefits of trabectedin ([@bib13]). However, the identification of a genomic DNA-based signature would be more adapted to routine practice than biomarkers including RNA expression data. RNA is less stable than DNA and consensual definition of cut-off levels for low or high expression is challenging. We have previously shown preliminary data from 44 patients suggesting that a specific *BRCA1* haplotype composed of four single-nucleotide polymorphisms (SNPs) may be associated with clinical benefit of trabectedin in STS patients ([@bib13]). We report here a larger study exploring the predictive value of such a DNA-based biomarker.

Materials and methods
=====================

Patients
--------

This study included four cohorts of consenting patients, with advanced STS treated between 1999 and 2012. Cohort 1 ([Table 1](#tbl1){ref-type="table"}): a cohort of 135 patients treated with trabectedin as part of two published phase 2 trials ([@bib16]; [@bib7]) or during a compassionate-use programme open to patients with all types of STS who had failed conventional chemotherapy for advanced disease ([@bib2]).Cohort 2 ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}): a cohort of 44 patients with advanced STS treated with an anthracycline-based chemotherapy. This cohort was used as an independent control cohort in order to validate the specific predictive value of the *BRCA1* haplotype for trabectedin response.Cohort 3 ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}): an independent cohort of 85 patients with localised STS treated with surgery and adjuvant radiotherapy that was used to explore an intrinsic prognostic value of *BRCA1* haplotype.Cohort 4: a validation cohort of 11 patients that was used to explore the feasibility of *BRCA1* haplotype testing from blood samples by comparing the constitutional and the tumour *BRCA1* haplotypes of consenting patients for whom blood and tumour samples were available.

The design of this study was exploratory. Therefore, no sample size calculation was performed and the inclusion of patients was based on availability of tumour material and/or blood for molecular experiments. This study was approved by the institutional review board (IRB) of each participating institution. All patients provided informed consent.

Treatment and response assessment
---------------------------------

Trabectedin was given to cohort 1 patients as previously described at a dose of 1.3--1.5 mg m^−2^ in the majority of cases with either a 3-h infusion or a 24-h continuous infusion schedule ([@bib9]; [@bib16]; [@bib7]). Tumour assessment (by computed tomography or magnetic resonance imaging) was usually performed every 8 weeks for all patients using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 ([@bib23]).

Genotyping of *BRCA1* SNPs
--------------------------

Genomic DNA was extracted from paraffin-embedded tissues according to previously published procedures ([@bib13]). For Holland Bouin-fixed tissues, sections were washed with lithium carbonate to remove picric acid. Tissues were then washed with 1 × TNE (10 m[M]{.smallcaps} Tris, pH 8; 1 m[M]{.smallcaps} EDTA, pH 8; and 100 m[M]{.smallcaps} NaCl). DNA was then purified on GFX columns (GE Healthcare Europe GmbH, Saclay, France) following digestion with proteinase K (2 mgml^−1^, 55 °C for at least 2 h).

For the first cohort, genotyping of the four *BRCA1* SNPs (Gly742Glu, rs16941; Arg1183Lys, rs16942; Gly1613Ser, rs1799966 and Pro871Leu, and rs799917) was carried out using the GoldenGate technology from Illumina (San Diego, CA, USA) on the BeadArray platform following the manufacturer\'s recommendations using 150 ng of genomic DNA per patient as starting material. Raw hybridisation intensity data processing, clustering, and genotype calling were carried out using the genotyping module in the GenomeStudio package (Illumina).

*BRCA1* SNP genotyping was also carried out via pyrosequencing. Briefly, 100 ng of genomic DNA were amplified with specific primers. Pyrosequencing primers were designed using the Pyrosequencing SNP Primer Design (V 1.01) software (Qiagen, Courtaboeuf, France). For PCR, 10 pmol of each primer (forward 5′-biotinylated: 5′-CACCACTTTTTCCCATCAAGTC-3′, reverse primer: 5′-TGGCCCTCTGTTTCTACCTAGTT-3′, for rs16941;forward: 5′-AGCCTATGGGAAGTAGTCATGC-3′, reverse 5′-biotinylated primer: 5′ GCCAAATGTGTATGGGTGAAAG-3′, for rs16942; forward 5′-biotinylated: 5′-TGGCAACATACCATCTTCAACC-3′, reverse: 5′-GGCTTCTCCCTGCTCACACTTT-3′ for rs179966; forward: 5′-AAGGTTTCAAAGCGCCAGTC-3′, reverse 5′-biotinylated: 5′-CTCTTCTGCATTTCCTGGATTTGA-3′ for rs 799 917) were used. The reaction was completed in a buffer containing 3 m[M]{.smallcaps} MgCl~2~ and 0.5 U Taq polymerase Platinum (Invitrogen, Cergy Pontoise, France) in a 50 *μ*l final volume. The mixture was denatured for 5 min at 95 °C and then 50 cycles were carried out: 30 s at 95 °C, 30 s at 60 °C, or 62 °C; and 30 s at 72 °C for rs16941 and rs16942, or rs179966 and rs799917, respectively. For pyrosequencing, ssDNA was prepared from 40 *μ*l of biotinylated PCR product using streptavidin-coated sepharose beads (GE Healthcare), and 0.37 *μ*[M]{.smallcaps} of the adequate sequencing probe (5′-CATTAATATTGCTTGAGCTG-3′ for rs16941, 5′-GCAAAAGCGTCCAGA-3′ for rs16942, 5′-GAGCAGCAGCTGGAC-3′ for rs179966 and 5′-CGCCAGTCATTTGCTC-3′ for rs799917) for analysis. Sequencing was performed with the SNP Gold reagent kit (Qiagen) according to the manufacturer\'s instructions.

For *BRCA1*, haplotypes and frequency estimation were obtained using the Haploview software ([@bib1]). DNA extractions and SNP determination were centralised at the INSERM U916 research laboratory.

Statistical analyses
--------------------

The statistical analyses on baseline demographics and clinical outcomes are based on all data available up to the cut-off date of 31 December 2013. Descriptive statistics were used to show the distribution of variables in the population. The 6-month nonprogression rate (clinical benefit rate, CBR) was defined as the number of patients whose tumours did not progress according to RECIST criteria during the first 6 months. Patients who died within 6 months of treatment onset were considered as events (progressive disease).

Progression-free survival (PFS) was defined as the interval between the date of the first cycle of chemotherapy (cohorts 1 and 2) and the time of progression according to RECIST criteria, death or last follow-up. Overall survival was defined as the interval between the date of the first cycle of chemotherapy (cohorts 1 and 2) or surgery (cohort 3), and the time of death or last follow-up. Overall survival rates were estimated with the Kaplan--Meier method and compared using the log-rank test. Univariate analyses of the association between OS and tumour characteristics included the following variables: age (\<52/⩾52), gender, grade (⩽2/3), histological subtype (liposarcoma or leiomyosarcoma/ other), number of metastatic sites (⩽1/⩾2), and *BRCA1* haplotype (at least one AAG allele/no AAG allele).

Pearson\'s correlation coefficient was used to assess the relationship between germline and tumour *BRCA1* haplotype (*r*=1, perfect correlation). Analyses were performed using SPSS 19.0 statistical software (IPSS Inc., Chicago, IL, USA). All statistical tests were two sided, and *P*\<0.05 was considered as statistically significant.

Results
=======

Patients and treatment
----------------------

The main study population included 135 patients. Their characteristics are described in [Table 1](#tbl1){ref-type="table"}. A total of 704 trabectedin cycles were administered. The median number of cycles per patient was three (range: 1--23).

BRCA1 status
------------

Among the 12 possible haplotypes, two (AAAG and GGGA) haplotypes covered ∼90% of the population (48.8% and 35.9%, respectively). Other haplotypes represented ∼10%. Patients were categorised into two subgroups based on the presence of the most frequent haplotype (AAAG): patients with at least one AAAG allele (*n*=99) and patients with no AAAG allele (*n*=36).

Survival
--------

The median follow-up was 32.7 months (range 24.7--40.4). One complete response, 16 partial responses, and 28 disease stabilisations lasting \>6 months were observed. The 6-month nonprogression rate (CBR) was 33.5%. At the time of analysis, 106 patients had died and 29 were still alive. Median OS was 12.2 months (95% confidence interval (CI): 9.3--15.1). Six-month and 1-year OS rates were 65.4% (95% CI: 62--68) and 51.3% (95% CI: 48.4--54.2), respectively ([Figure 1](#fig1){ref-type="fig"}).

Clinical benefit rate and survival according to *BRCA1* haplotype---subgroup analyses
-------------------------------------------------------------------------------------

At 33.7%, the 6-month CBR rate was significantly higher in the group of patients with at least one AAAG allele *vs* 13.0% in patients with no AAAG allele, *P*=0.01. The same trend was observed for PFS (log-rank Mantel-Cox: *P*= 0.056) and OS (log-rank Mantel-Cox: *P*=0.01) ([Figure 1](#fig1){ref-type="fig"}). We did not find any differences between 6-month CBRs for anthracycline-treated patients (34.5% in the group of patients with at least one AAAG allele vs. 50%, *P*=0.3), PFS (log-rank Mantel-Cox: *P*= 0.46), or OS (log-rank Mantel-Cox: *P*= 0.78) ([Figure 2](#fig2){ref-type="fig"}). We did not find any differences between outcomes in patients with localised STS managed with surgery plus radiotherapy according to *BRCA1* haplotype (log-rank Mantel-Cox: *P*= 0.34) ([Figure 2](#fig2){ref-type="fig"}).

Factors associated with OS
--------------------------

On univariate analysis, *BRCA1* haplotype was the only variable significantly associated with OS ([Table 2](#tbl2){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}).

Correlation between somatic and constitutional BRCA1 haplotype
--------------------------------------------------------------

The comparison of the constitutional and tumour *BRCA1* haplotype in 11 patients with available blood and tumour samples showed a similar status in all cases (10 cases with at least 1 AAAG allele, 1 case with no AAAG allele) (Pearson correlation coefficient *r*=1, *P*\<0.0001).

Discussion
==========

The *BRCA1* protein has a crucial role in DNA repair. It is not only essential for the repair of DSBs by homologous recombination, but it also allows cells to sense such lesions ([@bib18]).

Our study indicates a link between the *BRCA1* genotype and outcomes of sarcoma patients treated with trabectedin. Previous studies have mainly addressed the impact of *BRCA1* mutations on cell sensitivity to platinum compounds and have found that such alterations were associated with tumour sensitivity, probably because of reduced *BRCA1* activity ([@bib4]; [@bib3]; [@bib10]; [@bib15]). Analyses of several *BRCA1* SNPs have also identified haplotypes that may be associated with clinical outcomes in patients with gastric or lung cancer treated with platinum-based chemotherapies ([@bib14]; [@bib20]). *BRCA1* SNPs, whether they lead to amino-acid changes or not, may have a functional impact via several mechanisms. They could modify *BRCA1* protein function or stability, or they could alter *BRCA1* expression by acting on transcription, splicing, or translation. Whether the specific haplotype identified in our study is linked to a reduced activity of *BRCA1* in HR or altered expression remains to be investigated. However, our results indirectly support the role of HR in trabectedin-induced cytotoxicity.

Our study has methodological strengths that compensate at least in part the potential bias related to its retrospective nature. A predictive factor is a clinical or biological characteristic that provides information on the likely benefit from treatment (either in terms of tumour shrinkage or survival). Such predictive factors can be used to identify subpopulations of patients who are most likely to benefit from a given therapy. In contrast, a prognostic factor is a clinical or biological characteristic that is objectively measurable and that provides information on the likely outcome of the cancer in an untreated individual. Such prognostic markers are helpful for identifying patients with cancer who are at high risk of metastatic relapse and therefore potential candidates for adjuvant systemic treatments. Importantly, prognostic factors define the effects of patient or tumour characteristics on the patient outcome, whereas predictive factors define the effect of treatment on the tumour. By analysing an independent series of patients with localised STS, we have identified that the *BRCA1* haplotype has no impact on survival and therefore has no intrinsic prognostic value. This is in agreement with the fact that this gene was not included in the prognostic signature we recently identified ([@bib5]). Moreover, we found that the correlation between the *BRCA1* haplotype and outcome was limited to patients managed with trabectedin, as no such correlations were observed in an independent series of advanced STS patients managed with doxorubicin.

Despite the limitations mainly related to the retrospective design, our study suggests that the *BRCA1* haplotype may be a predictive factor of trabectedin efficacy in STS patients. As the unfavourable haplotype is present in about 25% of patients, these results may have obvious benefits for reducing the number of STS patients who ultimately receive this expensive drug, which exposes them to risks of adverse events without associated benefit. Such a DNA-based biomarker is easily assessable in routine practice as it requires only the availability of paraffin-embedded material, and it is probably also assessable in blood samples as we found the same *BRCA1* status in all cases tested (although this needs further confirmation in larger cohorts). The next step for the validation of this biomarker would be to demonstrate the predictive value of the *BRCA1* haplotype for trabectedin benefit in at least one randomised controlled trial comparing a trabectedin regimen to a trabectedin-free regimen. This would represent level A evidence that could modify the current conditions of trabectedin approval in STS patients.
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![Kaplan--Meier curve of PFS (**A**) and OS (**B**) according to *BRCA1* haplotype (green line: at least one AAAG allele, blue line: no AAAG allele).](bjc2014624f1){#fig1}

![Kaplan--Meier curves of overall survival according to *BRCA1* haplotype. (**A)** Advanced STS patients treated with doxorubicin; (**B**) localised STS patients treated with surgery and adjuvant radiotherapy.](bjc2014624f2){#fig2}

###### Patient characteristics (*n*=135)

  **Characteristics**               **No. of Patients**  **%**
  -------------------------------- --------------------- -------
  Median age, years (range)             52 (18--74)       
  **Sex**                                                
  Male                                      57           42.0
  Female                                    78           58.0
  **Histological subtype**                               
  **Liposarcoma**                           20           15.0
   Myxoïd/round cell liposarcoma            12            
   Other                                     8            
  Leiomyosarcoma                            60           44.5
  Synovial sarcoma                          18           13.5
  Undifferentiated sarcoma                   8           6.0
  Other                                     29           21.0
  **Histological grade**                                 
  Grade 1                                    2           1.5
  Grade 2                                   35           26.0
  Grade 3                                   98           72.5
  **Number of metastatic sites**                         
  ⩽1                                        84           62.0
  ⩾2                                        51           38.0

###### Univariate analysis of factors associated with overall survival (OS)

  **Variable**                     ***P*****-value**
  -------------------------------- -------------------
  **Age (years)**                  
  \<52 *vs* ⩾52                    0.9
  **Gender**                       
  Male                              
  Female                           0.5
  **Grade**                        
  ⩽2                                
  3                                0.6
  **Histological subtype**         
  Leiomyosarcoma/liposarcoma        
  Other                            0.08
  **Number of metastatic sites**   
  ⩽1                                
  ⩾2                               0.5
  **Haplotype**                    
  At least one AAAG allele          
  No AAAG allele                   0.01

[^1]: Current address: INSERM U896, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France.
